EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial

Jacob Schultz, Gro Egholm, Mikael Kjær Poulsen, Bo Løfgren, Morten Würtz, Hanne Maare Søndergaard, Mads Jønsson Andersen, Jacob Valentin Hansen, Gratien Andersen, Shifan Thangavel, Søren Mellemkjær, Anushree Burade und 3 weitere

EuroIntervention · 2026-08 · 22 (16) · 903-912

DOI: 10.4244/eij-d-26-00292 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2026-08. Verfasst von Jacob Schultz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Pulmonary Embolism, Thrombolytic Therapy, Fibrinolytic Agents, Tissue Plasminogen Activator. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Catheter-directed thrombolysis (CDT) reduces the right-to-left ventricular ratio (RV/LV ratio) in patients with intermediate-risk pulmonary embolism (PE). Prior randomised studies comparing CDT to anticoagulation used ultrasound-assisted devices and high doses of thrombolytics with extended infusion durations, which may increase healthcare costs and complications, thereby limiting its clinical applicability. AIMS: We sought to evaluate the efficacy and safety of low-dose, short-duration CDT compared with unfractionated heparin (UFH) in patients with acute intermediate-high-risk PE. METHODS: In this open-label, randomised controlled trial, patients with acute intermediate-high-risk PE were randomised 1:1 to receive CDT (4 mg recombinant tissue plasminogen activator [r-tPA] per catheter over 2 hours) plus UFH or UFH alone. The primary endpoint was the change in RV/LV ratio at 24 hours. Secondary endpoints included thrombus burden reduction, changes in vital signs and echocardiographic measures of RV function, length of hospital stay, 30-day mortality, and 90-day recurrent PE. Safety endpoints included major and minor bleeding. RESULTS: Between August 2020 and October 2024, 60 patients were randomised, with 58 completing follow-up (CDT: n=29; UFH: n=29). CDT plus UFH improved the RV/LV ratio at 24 hours compared with UFH alone (-0.17 vs +0.02; p=0.01). Secondary endpoints did not differ between groups. One death occurred in the UFH group. One patient experienced haemodynamic deterioration during CDT, successfully managed with additional r-tPA. No major bleeding occurred. Minor bleeding occurred in three patients (10%) in the CDT group and one (3%) in the UFH group (p=0.29). CONCLUSIONS: Low-dose, short-duration CDT plus UFH improved the RV/LV ratio without increasing major bleeding compared with UFH alone in intermediate-high-risk PE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismThrombolytic TherapyFibrinolytic AgentsTissue Plasminogen ActivatorHeparinHumansFemaleMaleAgedMiddle AgedTreatment OutcomeAnticoagulants

Substanzen

Fibrinolytic AgentsTissue Plasminogen ActivatorHeparinAnticoagulants

Autor:innen und Institutionen

  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Cardiology, Odense University Hospital, Odense, Denmark.
  • Department of Medicine, Randers Regional Hospital, Randers, Denmark.
  • Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Department of Cardiology, Gødstrup Regional Hospital, Herning, Denmark.

Zitieren

APA

Schultz, J., Egholm, G., Poulsen, M. K., Løfgren, B., Würtz, M., Søndergaard, H. M., Andersen, M. J., Hansen, J. V., Andersen, G., Thangavel, S., Mellemkjær, S., Burade, A., Kalra, M., Nielsen-Kudsk, J. E., & Andersen, A. (2026). Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial. EuroIntervention, 22(16), 903-912. https://doi.org/10.4244/eij-d-26-00292

Vancouver

Schultz J, Egholm G, Poulsen MK, Løfgren B, Würtz M, Søndergaard HM, et al. Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial. EuroIntervention. 2026;22(16):903-912. doi:10.4244/eij-d-26-00292

BibTeX
@article{Schultz2026,
  author = {Schultz, Jacob and Egholm, Gro and Poulsen, Mikael Kjær and Løfgren, Bo and Würtz, Morten and Søndergaard, Hanne Maare and Andersen, Mads Jønsson and Hansen, Jacob Valentin and Andersen, Gratien and Thangavel, Shifan and Mellemkjær, Søren and Burade, Anushree and Kalra, Mannudeep and Nielsen-Kudsk, Jens Erik and Andersen, Asger},
  title = {Low-dose, short-duration catheter-directed thrombolysis for acute intermediate-high-risk pulmonary embolism: the BETULA trial},
  journal = {EuroIntervention},
  year = {2026},
  volume = {22},
  number = {16},
  pages = {903--912},
  doi = {10.4244/eij-d-26-00292}
}
Kostenlos starten →